Get the Stockscreener App
3.75
8.07%
0.28
Checkpoint Therapeutics Inc stock is traded at $3.75, with a volume of 838.26K.
It is up +8.07% in the last 24 hours and up +18.67% over the past month.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.
See More
Previous Close:
$3.47
Open:
$3.49
24h Volume:
838.26K
Relative Volume:
1.26
Market Cap:
$177.99M
Revenue:
$103.00K
Net Income/Loss:
$-42.47M
P/E Ratio:
-0.6906
EPS:
-5.43
Net Cash Flow:
$-34.30M
1W Performance:
+9.33%
1M Performance:
+18.67%
6M Performance:
+102.70%
1Y Performance:
+79.43%
1-Day Range:
$3.46
$3.81
1-Week Range:
$3.25
$3.81
52-Week Range:
$1.36
$3.97
Checkpoint Therapeutics Inc Stock (CKPT) Company Profile
Name
Checkpoint Therapeutics Inc
Sector
Industry
Phone
781-652-4500
Address
95 SAWYER ROAD, WALTHAM, NY
Compare CKPT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| CKPT | 3.75 | 177.99M | 103.00K | -42.47M | -34.30M | -5.43 |
| VRTX | 450.97 | 116.38B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 82.09B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.14B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.25B | 3.30B | -501.07M | 1.03B | 11.54 |
Checkpoint Therapeutics Inc Stock (CKPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-14-22 | Resumed | B. Riley Securities | Buy |
| Jun-09-21 | Initiated | B. Riley Securities | Buy |
| Jan-20-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-29-19 | Initiated | Lake Street | Buy |
| Dec-08-17 | Initiated | H.C. Wainwright | Buy |
Checkpoint Therapeutics Inc Stock (CKPT) Latest News
Valora Therapeutics Raises $30 Million Seed Financing from Top Investors to Transform Immunotherapy with a Novel Glyco-immune Checkpoint Platform - Business Wire
Investigation announced for Long-Term Investors in shares - openPR
Checkpoint Therapeutics’ (CKPT) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Research Analysts Offer Predictions for CKPT FY2024 Earnings - MarketBeat
Checkpoint Therapeutics Third Quarter 2024 Earnings: US$0.23 loss per share (vs US$0.29 loss in 3Q 2023) - Yahoo Finance
ARMISTICE CAPITAL, LLC Acquires Significant Stake in Checkpoint Therapeutics Inc - GuruFocus.com
Checkpoint Therapeutics: Preparing For Cosibelimab’s Upcoming PDUFA Date (NASDAQ:CKPT) - Seeking Alpha
Caterpillar Inc (CAT-N) QuotePress Release - The Globe and Mail
Tesla Inc (TSLA-Q) QuotePress Release - The Globe and Mail
Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates - GlobeNewswire
TSX Utilities Capped Index (TTUT) QuotePress Release - The Globe and Mail
Checkpoint Therapeutics Sets FDA Review Date, Secures $9.2M Funding Boost Amid Q3 Loss | FBIO Stock News - StockTitan
S&P Midcap Micro (OMZ23) Quote - The Globe and Mail
S&P 500 ESG (ESG) QuotePress Release - The Globe and Mail
Vimeo Inc (VMEO-Q) QuotePress Release - The Globe and Mail
What Analysts Were Expecting After Checkpoint Therapeutics Inc (NASDAQ: CKPT) rose 2.03% - Stocks Register
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims o - GuruFocus.com
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Short Interest Update - MarketBeat
Kadant Inc (KAI-N) QuotePress Release - The Globe and Mail
Checkpoint Therapeutics stock hits 52-week high at $3.62 By Investing.com - Investing.com Australia
Checkpoint Therapeutics stock hits 52-week high at $3.62 - Investing.com
Checkpoint Therapeutics Inc (CKPT) Is A Good Stock To Invest In - Stocks Register
Lucid Group Inc (LCID-Q) QuotePress Release - The Globe and Mail
Boston-area biotechs await drug approval decisions in coming months - The Business Journals
Do investors need to be concerned about Checkpoint Therapeutics Inc (CKPT)? - US Post News
Checkpoint Therapeutics Inc [CKPT] CEO, President and Director makes an insider sale of 24,610 shares worth $50450.0. – Knox Daily - Knox Daily
Checkpoint Therapeutics Inc (CKPT)’s results reveal risk - US Post News
Janux Therapeutics Inc [JANX] Stock sold by Insider Avalon Ventures XI, L.P. for $5.18 million - Knox Daily
Understanding the Risks of Investing in Harrow Inc (HROW) - Knox Daily
Checkpoint Therapeutics Inc [CKPT] stock was sold by Oliviero James F III at the price of US$50450.0 - Knox Daily
Recent Insider Activity Suggests Potential Gains for Corcept Therapeutics Inc (CORT) - Knox Daily
Acadia Pharmaceuticals Inc (ACAD) Becoming More Attractive for Investors - Knox Daily
Gain Therapeutics Inc [GANX] Investment Guide: What You Need to Know - Knox Daily
Viridian Therapeutics Inc (VRDN) receives a Buy rating from Needham - Knox Daily
Liberty Energy Inc [LBRT] Investment Appeal on the Rise - Knox Daily
Surf Air Mobility Inc [SRFM] Investment Guide: What You Need to Know - Knox Daily
Recent Insider Activity Could Benefit Opendoor Technologies Inc (OPEN) - Knox Daily
Howmet Aerospace Inc [HWM] Insider Activity: An Update for Investors - Knox Daily
Zentalis Pharmaceuticals Inc [ZNTL] Insider Vultaggio Vincent sells 1,603 Shares – Company Insider Activity - Knox Daily
Checking in on TG Therapeutics Inc (TGTX) after recent insiders movement - Knox Daily
Investing in SS&C Technologies Holdings Inc (SSNC): What You Must Know - Knox Daily
KBR Inc [KBR] stock was sold by Ibrahim Jalal at the price of US$2.33 million - Knox Daily
Confluent Inc (CFLT) receives a Neutral rating from Robert W. Baird - Knox Daily
Alnylam Pharmaceuticals Inc’s latest rating changes from various analysts - Knox Daily
The Attractiveness of Investing In Cerence Inc (CRNC) is Growing - Knox Daily
PHAT (Phathom Pharmaceuticals Inc) may reap gains as insiders became active recently - Knox Daily
KPTI’s latest rating updates from top analysts. - Knox Daily
Enphase Energy Inc (ENPH) receives a Mkt perform rating from William Blair - Knox Daily
Consol Energy Inc (CEIX) Becoming More Attractive for Investors - Knox Daily
Investing in Myriad Genetics, Inc. (MYGN): What You Must Know - Knox Daily
Rocket Pharmaceuticals Inc’s latest rating changes from various analysts - Knox Daily
Checkpoint Therapeutics Inc Stock (CKPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.89%
2.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):